Bristol-Myers Squibb Company
BMY
Jodie situation report
Bristol-Myers Squibb Company's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 15 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 28 directly disclosed connections are confirming.
- Quarter and year-to-date revenue growth for Opdivo Qvantig following its 2025 launch.
- Sharp quarterly and year-to-date revenue decline for Pomalyst/Imnovid attributed to generic erosion in the U.S.
Invalidation: The isolated read changes if BMY's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind BMY
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ZBIOZenas BioPharma, Inc.partnerFeb 11, 2026 ▾
“The IDMC recommended that the other two Phase III trials, Librexia AF for patients with atrial fibrillation AF and Librexia STROKE for secondary stroke prevention, continue as planned, with topline data expected in 2026.”
BNTXBioNTech SEpartnerOct 30, 2025 ▾
“BioNTech In June 2025, BMS and BioNTech entered into a global strategic collaboration for the co-development and co-commercialization of pumitamig (BNT327/BMS986545), a bispecific antibody targeting PD-L1 and VEGF-A, which is currently being evaluated in a Ph…”
Depended on by
PRTAProthena Corporation plcpartnerMay 7, 2026 ▾
“Our active clinical portfolio includes prasinezumab currently being evaluated in the Phase 3 PARAISO clinical trial for the treatment of early Parkinson’s disease in partnership with Roche, coramitug currently being evaluated in the Phase 3 CLEOPATTRA clinica…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 25 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
BMY is currently a Follower in the organic co-movement group Drug Manufacturers - General. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.